Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Moroctocog Alfa (AF-CC) Prophylaxis in Indian Hemophilia A Patients
NCT04396639Phase 4Completed
- Sponsor
- Pfizer
- Start
- Jan 2020
- Primary completion
- Sep 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of moroctocog alfa in hemophilia A, sponsored by Pfizer. Primary endpoint: Percentage of Participants Who Developed Factor VIII (FVIII) Inhibitors up to 8 weeks. Started Jan 2020; status: completed.
02
Drugs
moroctocog alfa
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT04396639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04396639.